Speedy Filler Produces 200,000 capsules/hr

Article

Speedy Filler Produces 200,000 capsules/hr

At INTERPHEX MG America will showcase the G250 Capsule Filler, which can dose powders, pellets (two different kinds in same capsule), micro-tablets and tablets – and varying combinations – at speeds up to 200,000 capsules/hr. Dosing supervision and control is incorporated throughout the G250’s operation cycle. The machine’s functions are managed by an industrial, Windows XP Embedded color monitor PC.

MG America, Fairfield, NJ
• www.mgamerica.com • tel. 973.808.8185
INTERPHEX Booth #2253

Recent Videos
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Pharm Tech Group looks at the challenges surrounding the development and manufacture of ATMPs in more detail with Agne Vaitkeviciene, CEO of Memel Biotech.
Pharm Tech Group sits down with Bernard Sagaert, CEO of etherna, to examine the role of mRNA in the treatment of autoimmune diseases.
Related Content
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

FDA Approves First Generics of Rivaroxaban Tablets

Patrick Lavery
March 12th 2025
Article

Rivaroxaban, long known under the brand name Xarelto, is an anticoagulant, a classification that is among the most-prescribed medications in the United States.

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

March 26th 2024
Podcast

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.

Two dosing pens of a fictitious semaglutide drug (GLP-1) on a scale facing a dumbbell. Concept for alternative ways to loose weight. | Image Credit: © Andreas Prott - Stock.adobe.com

Next-Generation Anti-Obesity Medicines

Cheryl Barton
February 8th 2025
Article

European biopharma companies are looking beyond GLP-1s.

Drug Solutions Podcast: mRNA Past, Present, and Future

Drug Solutions Podcast: mRNA Past, Present, and Future

Chris Spivey
August 17th 2023
Podcast

An mRNA conversation about the recent past, current hot topics, and probable future.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

With New Funding, Orbis Medicines to Develop Oral Macrocycles as Alternative to Biologic Drugs

Feliza Mirasol
January 7th 2025
Article

With the new $94 million (€90 million) funding, the company will develop its pipeline of oral macrocycle drugs, nCycles, against validated biologic targets.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Takeda Receives Japanese Regulatory Approval for HYQVIA Subcutaneous Injection for Treating Agammaglobulinemia or Hypogammaglobulinemia

Feliza Mirasol
January 4th 2025
Article

With this approval, HYQVIA [Immune Globulin Infusion 10% (human) with Recombinant Human Hyaluronidase] becomes the first and only facilitated subcutaneous immunoglobulin available in Japan to treat these disorders.